List of CAR-T Immunotherapy Companies in United States - 168

At 100XBIO we strive to deliver 100x more data on antigen specificity of the T cells in the limited sample volume (blood, tumor, lymph nodes), and as the downstream -- confirming the cells' phenotype and cytokine expression. Looking for (1) early investments, (2) R&D partners, and (3) early academia, biotech and pharma clients. We are raising $500K of pre-seed investment, and raised over $200K.

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to “think” smarter and faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

4immune Therapeutics has developed the first CAR T therapy to target and destroy the autoreactive T cells responsible for specific autoimmune disorders. Our multi-component CAR system with its novel adaptor molecule (CAL) bridges autologous or allogeneic CAR T cells to the offending autoreactive T cells to kill the cells and stop the disease in its tracks. Our first therapeutic targets early-stage type 1 diabetes, presently an incurable disease. There are many excellent therapies that successfully tamper down symptoms or prolong onset of the disease and have enhanced the quality of life for many patients. Others are achieving therapeutic value with beta cells transplants for late-stage patients. Our mission is to eradicate the disease-causing cells early in the process before too much pancreatic tissue damage has ensued and conquer autoimmune disorders for life.

A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.

Aavocyte, Inc. is a biotech company registered in the State of Washington in 2019. Aavocyte specializes in developing various precise targeting T cell immunotherapy products to treat solid tumors.

Our Mission To create best niche antibody-based biologics for fulfilling the research and development needs in biomedical and biopharmaceutical communities. Our long range goal is to develop therapeutic and diagnostic entities. Core Competence ABB's core competence is in protein designs of biologics for diagnostic and therapeutic applications of immuno-oncological disorders. Specifically, our R&D for therapeutics is focused on biologics that are capable of modulating activities associated with antigenic targets and effector molecules. In addition, ABB has designed and produced a panel of immune related protein reagents that are available to biomedical researchers as investigational tools. History Founded in 2007, AB Biosciences (ABB) has been dedicated to the engineering of therapeutic biologics and research protein reagents. With decades of combined experience in research and development, ABB's scientists have built an efficient platform for the development of these two protein classes. The recombinant replacement of the traditional IVIG (PRIM program) is a great example of our engineering expertise in R&D of an unique protein drug for replacing the traditional serum-derived IVIG. Our Community Massachusetts provides a vibrant and nurturing environment for life science ventures like ABB, in terms of training grants and tax benefits, as well as an abundant talent pool possessing a wide range of expertise. Discovering breakthrough biotechnology and exploring biologics for biomedical study is our mission at AB Biosciences. As part of our commitment to science education, we open our doors to intern students, who can experience firsthand the R&D employment possibilities in the Biotech Industry. More than 15 students/interns have visited our laboratory since 2009.

AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T and TIL therapies.

Driven by a bold founding vision: Empowering patients from within, Abintus is pioneering potentially curative, off-the-shelf genetic medicines that engineer cells directly inside the patient’s body, also termed in vivo. These therapies are based on Abintus' clinically proven Modular Delivery Platform (MDP). The company’s two initial, fit-for-purpose, In Vivo programs are: 1. Highly selective gene expression targeting cell type/state via synthetic biology (e.g., In Vivo CAR-NK/T/Treg, In Vivo TCR-T) with applications across multiple gene delivery systems (e.g., AAV, lenti, adeno, retro) and therapeutic areas including leukemia, solid tumors, autoimmune, infectious, and genetic disease. 2. Simultaneous engineering of a diverse repertoire of active innate and adaptive immune cells (e.g., In Vivo CAR-X) with applications in diseases such as lymphoma and solid tumors. Abintus is leveraging over 20 years and $275 million of prior technology advancement for in vivo engineering including the treatment of over 350 patients through Phase 3 registration trials. Our company name comes from the Latin words “ab intus”, which means “from within”. We chose this name for 3 reasons: 1) Patients: We are pursuing product candidates that are designed to directly empower patients’ own immune cells to fight their disease from within. 2) Science: Our team is committed to scientific excellence and continual learning. Our differentiated technologies have the potential to directly reprogram activated immune cells “in situ”, or from within. 3) Culture: We believe our ability to achieve our vision will come from within - by building a performance-driven culture that prioritizes career development and rewards outstanding contributions. Abintus’ initial funding syndicate included Takeda Ventures and The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP). Abintus Bio, Inc. (“Abintus”) is headquartered in San Diego. www.abintusbio.com.

Ablexis offers the AlivaMab® Mouse platform, a suite of transgenic mouse strains for human therapeutic antibody discovery. AlivaMab Mouse strains are uniquely designed to be better for human therapeutic antibody discovery and development, for applications across antibody drug discovery including highest quality IgGs, singe-domain VH, multispecifics, ADCs, CARs, TCRm, and other modalities. The AlivaMab Mouse strains are well-documented for generating drug-like antibodies with broad combinatorial and somatic diversities, high affinities, specificity, and excellent developability properties. Users of AlivaMab Mouse include the world’s largest pharmas, public and private biotechs, and leading academic institutions. AlivaMab Mouse-derived antibodies in clinical development span formats including IgG, multispecific, ADC, and CAR. Many partners use AlivaMab Mouse at Ablexis’ sister company, AlivaMab Biologics, a leading provider of services in antibody drug discovery, engineering, and protein sciences. Visit us at www.ablexis.com to learn more. For inquiries about licensing the AlivaMab Mouse, contact us at info@ablexis.com.

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics. Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.

At Adicet (Nasdaq: ACET), we are defined by our mission to deliver best-in-class gamma-delta T cell therapies for patients fighting autoimmune diseases and cancer. Every one of our team members, whether in the lab, manufacturing, or general business role, comes to work every day with the patient in mind. As pioneers in the cell therapy space, we are honored and humbled by the opportunity to put our talents to bear in developing transformative therapies to defeat autoimmune diseases and cancer. We believe that the best way to do this is through discovering and developing allogeneic gamma-delta T cell therapies, a novel type of cell therapy. Adicet has chosen the gamma-delta T cell because it: • Preferentially traffics to tissues and provides B cell depletion, potentially leading to an immune reset for patients with autoimmune diseases. • Has multiple ways to target and kill cancer cells including solid tumors. We also chose to use cells from donors (allogeneic) to enable our potential therapies to be readily available when needed (taken “off-the-shelf” or available to the patient on demand). We’re not just blazing new trails in cell therapy, we’re having fun along the way. With regular team gatherings, many shared meals, larger company events, and a consistent commitment to our values, we have a strong culture! We are proud to attract and retain some of the greatest talent in the biopharma and cell therapy space, and we’re consistently giving back to our employees. The Adicet benefits package includes generous financial compensation, comprehensive health plans, generous paid time-off, educational reimbursement, and access to many amenities in our state-of-the-art facility. To learn more or inquire about joining our team in Boston, MA or Redwood City, CA, please visit http://www.adicetbio.com

Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy. The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.

Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE).

Akadeum Life Sciences® has developed a next generation platform that solves long-standing problems across cell therapy and other research, diagnostic and therapeutic markets. The proprietary buoyant microbubble technology platform addresses the need for high cell quality, scalability, time and workflow that current magnetic particle-based products commonly used in cell therapy manufacturing and research can’t address. The Company has several GMP grade and Clinical Ready kits to enable each stage of cell therapy manufacturers pipeline. Harnessing the microbubble capability, the Alerion™ Microbubble Cell Separation System enables cell isolation from tens of billions of cells in apheresis material in under an hour, significantly expanding capacity of manufacturers. Akadeum is currently working with some of the largest corporations and forward-thinking leaders in the industry. The power of the Akadeum microbubble platform is an elegant and easy-to-use technology that can enable faster, more accurate, and scalable workflows to improve human health. Better Isolations. Healthier Cells.

Alaunos Therapeutics (previously Ziopharm Oncology, Inc.) a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient’s immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is based in Houston, Texas.

At Alaya.bio, we're developing a revolutionary targeting polymeric nanoparticle that enhances the transduction efficiency of quiescent cells such as T-cells, NK-cells, and stem cells. Our platform eliminates the need for activation factors or cytokines, resulting in reduced exhaustion of transduced cells while preserving their naive and memory phenotypes, leading to better clinical outcomes.

Aleta Biotherapeutics’ unique portfolio of multi-antigen targeting solutions for cell therapy address are designed to enable approved CAR T cell therapies to work better in B cell lymphoma, B cell leukemia and multiple myeloma. Our technology is designed to further enable CAR T cell therapies to successfully treat non-B cell cancers such as acute myeloid leukemia (AML), and solid tumors such as breast cancer, gastric cancer and pediatric brain tumors, an area where advances are desperately needed.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of AlloCAR T candidates across a portfolio of hematologic and solid tumors. The company was founded in 2017 and is headquartered in South San Francisco, California.

Alphageneron Pharmaceuticals, Inc., is a privately-held clinical stage biotechnology company, developing Antibody Drug Conjugates (ADCs) and natural killer (NK) cell therapies, supported by Companion Diagnostics. Our team are industry veterans with experience in both large pharma and biotechnology startups committed to transforming the lives of cancer patients.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Ananta has developed a centrifugal fluidized expansion (CentriFLEX) perfusion bioreactor that balances centrifugal forces with a continuous feed of fresh media. The CentriFLEX resolves a key manufacturing bottleneck in continuous cell culture. This instrument supplies fresh media, removes inhibitory cell waste, and prevents the loss of cell products.

Angeles Therapeutics is a next generation cell and immune therapy company based on the technology licensed from the laboratory of its founder @PreetChaudhary. Angeles has developed a novel CAR-T and CAR-NK platforms that provide physiological TCR signaling and overcomes most of the limitations of current generation CAR-T. Most importantly, our platform is highly effective against solid tumors. Angeles has also developed one of the largest portfolio of CAR-T and CAR-NK in the world targeting more than 130 antigens covering cancer, infection and immune disorders. Our platform is fully compatible with autologous, allogeneic, universal and bispecific approaches. Angeles has recently entered a partnership with a global major pharmaceutical company and is looking for additional partnership opportunities for further development of its portfolio.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company headquartered in the San Francisco Bay Area. We are advancing our product pipeline of improved cytokines (Exenokines, Mableukins etc) and tumor-targeting antibody drug conjugates. Our lead product, Exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. We specialize in the discovery and development of optimized immunotherapeutics, leveraging our core expertise in cancer immunotherapy, bioinformatics, and target-based protein evolution.

Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).

Arbele is a locally grown pharmaceutical biotech focused on immunotherapy of cancers, immune disorders and neurological diseases. The company founding team has a strong combination of business development and pharmaceutical R&D, with an accumulation of >30 year experience in multinational drug companies. Our motto is to excel patient healthcare through innovation and breakthrough. Our mission is to deliver innovative and cost-effective therapeutics to treat diseases of unmet needs. We focus on antibody-based therapeutic platforms, including chimeric antigen receptor (CAR)-T and Bi-specific antibody technology, while leveraging new technology on CRISPR genome editing. Our culture ingredients are “integrity and social values”.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company’s lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

At Artiva, our mission is to deliver to cancer patients highly effective cellular immunotherapies that are also safe and immediately accessible. Towards this end, Artiva is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, including CAR-NK cell therapies, that leverage the company’s unique manufacturing and engineering capabilities. Artiva is headquartered in San Diego.

Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.

AvenCell - Based on our deep science and focused on patients in need, we develop next generation immunotherapies for hard-to-treat cancers.

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Bio4t2 is a clinical stage bio pharmaceutical company developing novel single-target and combo-therapeutic CAR based cell therapies against solid cancers through its proprietary PrismCore platform that are fine-tuned to comprehensively target self-antigens in patients with solid tumors.

BioCentriq is a premier contract development and manufacturing organization (CDMO) dedicated to advancing cell therapy. Since 2019, the company has specialized in GMP autologous and allogeneic cell therapies, offering end-to-end clinical-to-commercial capable services tailored to clients’ unique needs. Operating from two state-of-the-art U.S.-based facilities, BioCentriq provides a comprehensive range of services, including technology transfer and new technology evaluations, process and analytical development, cGMP manufacturing, quality control lot release, and stability studies. The company’s expertise spans diverse cell therapy modalities, such as T-cell (CAR-T, TCR), NK-cell, iPSC, and MSC-based products. With its proprietary LEAP™ manufacturing platform, BioCentriq accelerates service timelines while offering standardized and customizable solutions, including traditional fee-for-service, hybrid and person-in-plant operations, dedicated cleanroom capacity, and flexible service and contract arrangements. In addition to its technical capabilities, BioCentriq operates the Cell and Gene Therapy Experiential Learning Center, a training facility which provides hands-on and virtual instruction under the guidance of industry-experienced instructors and subject matter experts. The program has trained hundreds of participants, hosted major pharmaceutical companies, and integrates next-generation technologies and concepts into its curriculum including: Industry 4.0 and Lean principles, predictive analytics, augmented reality, and electronic batch record systems. Backed by GC Corporation, a South Korea-based leader in the healthcare, pharmaceutical and biotechnology industry, BioCentriq combines global expertise with a flexible working relationship, set to empower clients to develop and deliver cutting-edge, personalized therapies with unmatched precision and efficiency.

BioTissue is the leader in innovative applications of human birth tissues for regenerative wound healing, aiming to improve patient outcomes. The company is committed to promoting regenerative healing through its birth tissue products.

bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of ß-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company’s product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases, as well as clinical trial collaboration with Magenta Therapeutics. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

We are a kids-first, clinical-stage biotechnology company focused on harnessing the power of CAR-T cell technology for tumors n the central nervous system (CNS), prioritizing pediatrics with plans to expand our technology to adult indications. We are building a platform to optimize the application of CAR-T technology in CNS tumors-- prioritizing diffuse intrinsic pontine glioma (DIPG) with plans to expand to other pediatric and adult brain tumors, including brain metastases.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company’s lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CancerVAX is a drug development company focused on developing novel therapeutics in the oncology space. In partnership with the UCLA School of Medicine, we are progressing two programs: 1) Ewing sarcoma; 2) Universal cancer vaccine. CancerVAX is privately funded

Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles conjugated with a recombinant protein binder such as monoclonal antibodies (tLNPs) designed to deliver payloads, including mRNA or gene editing tools, that can reprogram specific cell types in vivo. The platform technology has the potential to generate transformative therapies with applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders.

CaraVan Biologix is a biotechnology company focused on expanding the life-saving benefits of CAR-T cell therapeutics to the broader cancer patient population by addressing their limitations. Our underlying and core novel technologies enable the development of allogenic treatments for a spectrum of human diseases, including solid tumors and hard-to-treat cancers. Our therapeutic agents are expected to show superior safety profiles, including a low risk for cytokine release syndrome. Importantly, our technology will greatly reduce the complexities of manufacturing that are associated with whole-cell therapies, thereby minimizing the time, cost, and variability risk to facilitate greater access for patients in need.

CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

Cartesian Therapeutics is a fully integrated, clinical-stage biopharmaceutical company developing novel cell and gene immunotherapies to treat cancer and autoimmune diseases.

At Catamaran, our mission is to harness the power of our proprietary TAILWIND™ Platform to develop safe and effective, off-the-shelf, allogeneic immune cell therapies for the treatment of patients with cancer and immune disorders.

Celetrix is the leader in electroporation with our new high efficiency electroporation technologies for delivering DNA, RNA and proteins to cells. Celetrix provides technology and support for CAR-T manufacturing by transposon mediated expression and RNP mediated gene editing for T cells, stem cells and CD34+ HSC.

Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company's cloneXplorer and proprietary nanowell plates uniquely integrates both phenotypic and genomic data at massive scale (up to 100,000s of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology. Learn more at www.celldom.com and follow the company's growth @celldominc on Twitter.

Cellinfinitybio is a biotechnology company that pioneers massive directed evolution to unlock the infinite potential of cell therapy.

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.

Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company’s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. Century Therapeutics, Inc. has a research collaboration with Outpace Bio, Inc. for CAR engineering. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Chimera's mission is to reprogram life to end cancer, using therapies that restore dignity to patients. We do this with next generation, safer and more potent, CAR T therapeutics.

Chimeron Bio is a biotechnology company focused on developing personalized gene therapies, including self-amplifying RNA vaccines and therapeutics designed on its proprietary technology.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) is a biopharmaceutical company developing innovative cell therapy platforms for patients with cancer.

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.

CytoAgents is developing innovative pharmaceutical products to treat life-threatening conditions, diseases, and disorders associated with Cytokine Release Syndrome (CRS). Led by CEO Teresa Whalen, CytoAgents is comprised of seasoned business leaders and medical professionals focused on developing innovative treatments. The company is a clinical-stage biotechnology company with a therapeutic focus on oncology.

CytoImmune Therapeutics, LLC develops novel, coordinated immunotherapy solutions for patients. Our CoalesceNT™ platform harnesses the power of bispecific antibody (biAb) and chimeric antigen receptor (CAR) technology to coordinate an immune response with both natural killer (NK) and T cells. This combination of NK- and T-cell therapy expedites time-to-treatment and delivers a dynamic immune response that reflects natural immunity.

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive Flex-NK™ bispecific antibody and iPSC-derived, TALEN® gene-edited NK-cell platforms. FLEX-NK™ bispecific antibodies are built on a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology. The company is also developing three types of iPSC-derived NK (or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. ​ These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as relapsed multiple myeloma. Clinical studies are expected to initiate in 2023.

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com.

Dynamic Cell Therapies is developing controllable CAR T cells to address difficult-to-treat cancers. Our platform technology of dynamic control of engineered T cells will improve the safety, efficacy, and durability of CAR T cell therapies. This system will have immediate applications in hematological cancers, with future approaches in solid tumors and autoimmune diseases.

Eigen Therapeutics is a biotechnology company developing therapies that make cancer easier to find and eliminate. Eigen is focused on the development of 'priming' therapies that improve efficacy while reducing the toxicity of small molecule therapies.

Elpis Biopharmaceuticals is a biotechnology company focused on developing innovative cell therapies for cancer treatment. The company has a strong leadership team and has received significant funding to support its research and development efforts.

Developing transformative cancer medicines with CD19-Redirected ARTEMIS T Cells to improve patients’ lives

Eureka Therapeutics is a privately held biotechnology company located in the San Francisco Bay Area, focused on breakthrough immunotherapies for the treatment of cancer. Utilizing our antibody drug discovery and engineering technologies, we are advancing safe and effective therapies for targeting previously inaccessible cancer antigens. We have built an early stage pipeline of innovative drugs, with the most advanced candidates at pre-clinical stage. Eureka Therapeutics is a leader in the discovery of novel antibody immunotherapies. We utilize a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens. In collaboration with Memorial Sloan-Kettering Cancer Center, we were the first-to-demonstrate in vivo efficacy of a human IgG1 antibody against an intracellular cancer antigen. Our most advanced program is at preclinical stage and being developed in partnership with Novartis.

Excellos accelerates gene therapies by improving the quality, breadth, and variance of donor samples, and providing end-to-end cell therapy services: from customized collection to engineered working cell banks. Our proprietary Excellos 360 technology provides deep characterization of cells to better match patient and therapeutic development needs.

Expression Therapeutics, Inc. is a fully integrated clinical stage gene and cell therapy company developing novel, potentially curative, therapeutics for hematology and oncology. The Company, based in Atlanta, Georgia, has a state-of-the-art 43,000 square foot manufacturing facility in West Chester, Ohio. Expression Therapeutics, Inc. also built a state-of-the-art scalable 43,000 square foot manufacturing facility in Cincinnati, Ohio.

EXUMA Biotech is a clinical-stage biotechnology company committed to bringing to market cell & gene therapies for the treatment of cancer. Founded in 2015, The company has rapidly built its core technologies and a growing global presence with operations in China (Shanghai and Shenzhen), Grand Cayman, and headquarters in West Palm Beach, FL.

Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders.

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl.

GeneFab was formed in 2023 with a vision to combine industry leading expertise in synthetic biology with advanced cGMP capabilities to accelerate the development and commercialization of genetic medicines. GeneFab spins out from more than seven years at Senti Biosciences as the manufacturing and CMC arm of an innovative drug maker. Combining R&D collaboration, CDMO capabilities, drug development, and regulatory expertise is a key differentiator for GeneFab to support clients from early development to clinical and commercial manufacturing. The team is led by CEO Philip Lee who brings 20 years of experience as a biotech innovator and was most recently Co-Founder and CTO of Senti. GeneFab employs over 90 employees with a collective experience of 350+ years developing cell and gene therapies from discovery to commercialization.

Geneius Biotechnology, Inc. is a research company based out of 12 Michigan Dr, Natick, Massachusetts, United States.

GenTarget is a biotech company that specializes in lentivirus products for various applications.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

GlycoMantra is a biologics company developing novel therapeutics for unmet medical needs in metastatic castration-resistant prostate cancer, NASH liver disease, and other diseases.

GlyTR Therapeutics Inc. was co-founded by Professor Michael Demetriou and Dr. Raymond Zhou in 2016 to accelerate the application of GlyTR immunotherapy to treat cancer in humans. GlyTR overcomes many of the shortcomings of current immunotherapies by binding to never-before targeted tumor-associated glycans expressed in virtually all types of cancer. GlyTR Therapeutics Inc. has been incubating at EvoNexus in Irvine and has received support by UCI’s Applied Innovation Center located at The Cove.

GO Therapeutics is exploiting unique aspects of cancer cell biology to develop a new class of cancer therapies for previously intractable solid tumors. We target O-linked glycoproteins specific to cancer cells to develop proprietary, high-affinity antibodies to novel cancer-specific targets. Our antibodies are the basis for a broad array of potent cancer-killing modalities including T-cell bispecifics (TCBs), CAR-T, and antibody drug conjugates (ADCs). Each are designed to kill cancer while sparing healthy tissue.

Hemogenyx Pharmaceuticals PLC is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located at its state-of-the-art research facility in New York City. For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx Pharmaceuticals plc’s technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation. Hemogenyx Pharmaceuticals PLC is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The Company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

HighPassBio, an ElevateBio portfolio company, is working to advance a novel approach to treating hematological malignancies by leveraging T cell receptor (TCR)-engineered T cells, known as TCR T cells. The company’s lead program is designed to treat or potentially prevent relapse of leukemia in patients who have undergone hematopoietic stem cell transplant (HSCT). The technology was born out of Fred Hutchinson Cancer Research Center by world renowned expert, Dr. Marie Bleakley.

iCell Gene Therapeutics is developing Chimeric Antigen Receptor (CAR) engineered cells with improved functional properties and expanded applicability. We are a clinical stage company focused to demonstrate clinical proof of concept for unique, patent protected, targets and strategies. Our pipeline includes multiple additional first in man CAR strategies to target hematological cancers, non-hematological cancers and autoimmune disorders.

ImmPACT Bio is dedicated to the discovery of transformative CAR-T cell therapies for cancer patients who have exhausted their treatment options. Our technology is designed to precisely distinguish cancerous cells from normal cells; thereby eliminating tumors without damaging normal tissues. Our goal is to eradicate tumors without generating the severe side effects that are difficult, sometimes impossible, for cancer patients to endure.

Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.

Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. ICT has established a broad portfolio of CAR-T products to treat cancer patients. Some highlights of the company are provided below: Leading clinical data in solid tumor CAR-T Colorectal cancer: 3rd line treatment, ~50% PR/PMR (8/16) in dose escalation trial Activity in additional solid tumor indication including thyroid and pancreas Significant market opportunity in colorectal cancer and other solid tumor cancers Lead program in colorectal cancer: Estimated 53,2001 deaths (#2 cancer death) in the U.S. in 2020 Platform technology for solid tumors, which comprise 91% of new cancer cases Strong global IP protection CoupledCAR®, ArmoredCAR®, and other ICT technologies protected by ~200 patents/patent applications globally, including for U.S., Europe, China and Japan

Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/ .

Interius is an early-stage biotechnology company expanding the potential of cell and gene therapy by developing next-generation delivery technology based on inventions from the laboratory of Dr. Saar Gill at the University of Pennsylvania.

IO Biosciences develops allogeneic, gene modified cell therapies that treat cancers. Leveraging a proprietary lifesaving gene editing system and cell source, we create a unique opportunity to develop and manufacture of-the-shelf gene modified cell therapies. Taking vision from concept to reality - literally starting as a virtual, home-based biotech start-up last year, IO Biosciences has evolved to a team of 5 with office space and lab facility. Our state of the art CRISPOR gene editing methods create a new generation of universal “plug and play” cell sources for research and gene modified cell therapies treating cancers. This innovative system allows current personalized therapies to be transformed into manufactured off-the-shelf treatments and will greatly improve patient access at a competitive price point.

IPS HEART is the first induced pluripotent stem cell company to launch in 2014 around heart disease. With over $20 million+ of funded research, we were the first to publish our moon-shot approach showing extensive heart regeneration after heart attack with over 50%+ EF improvement vs control and a 70% reduction in fibrosis. We have created extensive new functional human heart muscle in our published studies thus validating our patented IPS small molecule platform approach. With a completed FDA PRE-IND meeting and GMP manufacturing, we plan to file the first IPS IND to start clinically in the United States.

iRepertoire was the first to develop and commercialize immune repertoire sequencing technology and products. iRepertoire uses immune repertoire sequencing technology to access the body’s immunological memory, or “logbook” of all past infection and disease. Sequencing the immune repertoire can yield insights into the nature of the body’s immune response to disease and infection. The future market for iRepertoire will be in clinical and research applications that require immune assessment such as drug treatment monitoring, identification of minimal residual disease (MRD), immune monitoring after stem cell transplantation, vaccine studies, and biomarker development.  iRepertoire provides primer kits and amplification to sequencing services to examine the TCR and BCR immune diversity in both humans and mice. iRepertoire also offers access to its proprietary repertoire analysis tools with the purchase of its regent systems.  iRepertoire’s reagent systems allow researchers to easily and inexpensively generate their own Next Generation Sequencing libraries in the convenience of their laboratory and analyze their data with the iRepertoire’s proprietary software pipeline at no additional cost.This year, iRepertoire has launched automated immune repertoire amplification and extraction on their sister company’s iC-processor (iCubate, Inc.). iRepertoire is proud to be a part of the non-profit initiative R10K, or Repertoire 10,000, with the HudsonAlpha Institute for Biotechnology, which aims to study the immune repertoire of 100 different diseases. The company has developed two key indices to describe the immune repertoire, i.e., the diversity index and the sharing index. These indices allow iRepertoire to identify disease specific signatures for diagnosis, prognosis, and treatment guidance.

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

JURA Bio, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2017. The company focuses on developing genomic medicines, particularly in immune-mediated therapies. JURA Bio utilizes computational and synthetic biology to create innovative treatments for diseases like cancer and autoimmune disorders. The company specializes in engineered cell-based therapeutics, including TCR therapies that target specific cancers by developing T-cell receptors. JURA Bio also employs a machine learning-guided platform to streamline the design and testing of protein-based therapies. One of their products, RedPoint, is part of their protein generation capabilities. JURA Bio operates within the healthcare and medical research sectors, aiming to enhance the safety and efficacy of its therapies.

KiraGen Bio is pioneering the next wave of cancer treatment through AI-driven, multiplex gene-edited CAR-T cell therapies, targeting the challenging realm of solid tumors. Despite the transformative success of cell therapies in hematologic cancers, solid tumors — which constitute the majority of cancer cases — have remained elusive to current treatments due to their complex tumor microenvironment (TME). Our mission is to breach this final frontier, leveraging our proprietary AI platform and combinatorial gene editing to design CAR-T cells capable of overcoming the immunosuppressive barriers of the TME. Founded on the belief that every cancer patient deserves a chance at a cure, KiraGen Bio combines the latest in biotechnology and computational science to bring innovative therapies from the lab to the clinic. Our team, comprised of experts in oncology, immunology, gene editing, and artificial intelligence, is dedicated to creating effective, durable treatments for solid tumors. KiraGen Bio stands at the intersection of innovation and hope, where cutting-edge science meets the urgent need for more effective cancer treatments. Our integrated approach spans from discovery through clinical development, embodying a commitment to excellence, patient-centricity, and the relentless pursuit of curing cancer. Join us as we work to transform the landscape of cancer therapy and bring new hope to millions of patients worldwide.

Kiromic BioPharma is an allogeneic Gamma Delta T-cell therapy company featuring unique, proprietary, end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors. We are a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic’s DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.

At Kite, a Gilead Company, our singular focus is cell therapy to treat and potentially cure cancer. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. Since 2009, Kite has been at the forefront of cancer immunotherapy. Today, we are proud to be the leader in engineered T cell therapy for hematologic malignancies, but we recognize that this is just the beginning. Patients are at the heart of our focus on the cure, which is why we are committed to pursuing cell therapy as a transformative treatment option for as many people with cancer as possible who may benefit. Cancer is personal to us. Unlike traditional pharmaceutical manufacturing, our therapies are not created on an assembly line. Cell therapy specialists at our manufacturing facilities reengineer a patient’s own immune cells to attack and fight their cancer cells — one patient at a time. That sense of connection to the people we serve motivates us daily at Kite. Our corporate headquarters are located in Santa Monica, California, and we have dedicated cell therapy manufacturing facilities in California, Maryland and the Netherlands. If you’re passionate about changing the future of cancer treatment, let’s talk.

Kyverna Therapeutics is a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna’s pipeline includes KYV-101, a fully human, autologous chimeric antigen receptor (CAR) T-cell therapy with properties well suited for use in B cell-driven autoimmune diseases and KYV-201, a fully human, allogeneic CAR T-cell therapy. By offering more than one mechanism for taming autoimmunity, and with patients currently in treatment for multiple indications in the U.S. and Europe, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated.

LEAH Laboratories is a biotechnology company that specializes in building living therapies for pets and their people.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen. The company is conducting multiple clinical trials to evaluate LCAR-B38M/JNJ-4528 as an earlier line of therapy for multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in Revlimid-refractory MM. It also has a broad portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, the company is developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL, which is currently in an investigator-initiated Phase 1 clinical trial in China. Further, it has various product candidates in early preclinical and clinical development for the treatment of solid tumors, as well as infectious diseases. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Luminary is a clinical stage CAR-T therapy company with a novel allogeneic manufacturing platform where our CAR and or TCR development utilizes gamma delta cells. What makes our allogeneic therapeutics unique are that our final drug product includes the combinatory power of both the Vẟ1 and Vẟ2 gamma delta cells giving our therapies the power of both innate and adaptive cancer clearing power. We have multiple solid tumor targets under development with a proprietary signaling method to ensure T-Cell persistence. Additionally, our Ligand BAFF CAR for hematologic cancers is designed with 3 antigen receptors specifically designed to overcome antigen escape.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bio's lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The company's pipeline is designed to expand on these early successes to more broadly impact other high-challenge cancers.

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

MedTherapy is a Boston-based global biotechnology corporation manufacturing cell, gene and immunological therapies for treatment of cancer to make them accessible and affordable for every cancer patient in the world. MedTherapy works in collaboration with Harvard Medical School, Merck, and the 'International Health Organization'​ (IHO) and many leading private and public instutions, organizations and biotechs. Cell, gene and immunological therapies comprise the most sophisticated treatments modern technology has developed. While their success has been deemed a ‘miracle’, however, unfortunately, their cost is exorbitant often running into millions of dollars which is not sustainable for any individual patient, society or country. Therefore, MedTherapy works in collaboration with various organizations- private, public, academia and non-profits in US and globally to develop more streamlined processes, technologies and partnerships to manufacture these sophisticated medical therapies and made affordable for every patient in the world.

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma.

Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. NCT04020575 is Minerva’s first-in-human trial of huMNC2-CAR44, a CAR T that targets the MUC1* growth factor receptor, for the treatment of metastatic breast cancers, 95% of which express a MUC1*. We are now expanding the current clinical trial to include our second CAR-T product that greatly increases persistence. The Company is rapidly accelerating its pipeline that includes next-gen CAR-T products, a straight antibody therapeutic and a small molecule therapeutic which are both for the treatment of cancer metastasis. Our track record of scientific breakthroughs is a testament to our visionary team and our collaborative culture. Join us in changing the world.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase 1/2 clinical trials.

NanoCell Therapeutics is a privately-held biotechnology company with offices in King of Prussia, Pennsylvania, and Utrecht, the Netherlands. Our mission is to revolutionize in-vivo cell engineering through our groundbreaking non-viral, DNA-based gene therapy platform, primarily focusing on oncology and autoimmune diseases. At NanoCell, we’re driving innovation by transforming traditional adoptive cell therapy methods into advanced in-vivo treatments. Our ultimate goal is to simplify the treatment process, increasing patient accessibility, potential clinical benefits, and cost-effective manufacturing. We work both autonomously and in collaboration with partners to make substantial advancements in our targeted disease areas. For more information, visit http://www.nanocelltx.com).

Nexcella, Inc. is a Los Angeles, California based clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our lead candidate, next generation BCMA-targeted CAR-T NXC-201 for relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma, has produced 100% and 95% response rates in each indication, respectively, as of December 10, 2023 across 72 patients. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma. We believe NXC-201 has the potential to be the world’s first “Single-Day CRS” CAR-T, enabling faster return home for patients. Expansion into autoimmune indications is planned. Our N-GENIUS platform allows us to discover, develop, and manufacture cutting-edge cell therapies for patients in need. To learn more about Nexcella, Inc. visit us at www.nexcella.com.

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.

Nona Biosciences is a global biotechnology company committed to providing a total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody discovery services range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging the advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs by diversified partnership strategies including co-discovery, platform and antibody discovery, and platform license. The values of the antibody discovery platforms and flexible partnership models have been well validated by more than 50 industry and academic partners within over 200 projects.

OmniAb is a leading-edge antibody discovery company that provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening. The company's discovery platform brings a high level of expertise and innovation to therapeutic antibody discovery.

Based in Rockville, Maryland, OncoC4 is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment.

Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with large unmet medical need. By leveraging pathways absent or minimally expressed in normal cells or tissue, we aim to inhibit cancer cell growth while reducing potential harm to healthy cells. We are pursuing trials in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), breast cancer, and Ewing sarcoma. Looking forward, we intend to rapidly broaden our pipeline and invest in the development of our innovative therapies across multiple cancers.

Orgenesis is a global biotech company that has been committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2012. Orgenesis established the POCare Network in 2020 to bring academia, hospitals, and Industry together to make these innovations more affordable and accessible to patients. In 2022, the POCare Services business unit responsible for developing and managing the decentralized POCare Centers and proprietary OMPULs was formed. Orgenesis will continue to focus on advancing to market through various partnerships its CGTs to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production.

Orna Therapeutics is a biotechnology company reshaping RNA therapeutics. We are developing the leading circular RNA technology platform (oRNA®) and unprecedented lipid nanoparticle (LNP) delivery solutions – unlocking the therapeutic possibilities of circular RNA and pioneering the next chapter of safe and effective in vivo therapies for the treatment of disease. Website: www.ornatx.com

Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the potency (OutSpacers™), specificity (Co-LOCKR™), and safety (EGFRopt™) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes. At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.

For decades, entrenched infrastructure barriers have slowed progress in the fight against cancer and the development of potent immunotherapies. The Parker Institute for Cancer Immunotherapy breaks down these barriers. The result is groundbreaking new research and an intellectual property model that builds collaboration between researchers, nonprofits and industry all working together to get treatments to patients faster.

PeproMene Bio, Inc is a clinical-stage biotech company in Irvine, California. We are committed to developing novel therapies to treat cancers and immune disorders. Our CAR T cells targeting an innovative tumor antigen (BAFF-R) for treating a broad range of B cell malignancies have a great potential to overcome the tumor relapse caused by antigen loss. We are working on bringing hope to those patients with such unmet medical needs.

Our mission at Poseida Therapeutics is to create cell and gene therapies with the capacity to cure. We are developing novel products using our broad gene engineering platform technologies, with the goal of bringing new and better treatments to patients with serious diseases, first in the blood-based cancer Multiple Myeloma and next in solid tumors like prostate cancer.

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing allogeneic CAR T and in vivo gene correction therapies for cancer and infectious diseases.

ProMab Biotechnologies, Inc is a revolutionizing biotechnology company that integrates cutting edge technologies to serve the global biomedical research community. We specialize in recombinant proteins, antibodies and engineered cell lines on which we are known to have built a superior reputation for quality and reliability. Our commitment to Excellence is exemplified by our newest service where we provide mRNA-LNP product and services that allows a swift and effective response to emerging infectious diseases. Join us in shaping the future of biotechnology and scientific progress. For more inquiries, visit our webiste: https://www.promab.com/. Email: info@promab.com

Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.

Regencor is a privately held regenerative medicine company targeting heart disease, the #1 cause of death in the United States. We have discovered and patented that the hypoglycosylated variant of a normal circulating human protein, Follistatin-like 1, (FSTL1) drives heart muscle cells within the infarct zone to undergo controlled proliferation, thereby restoring ventricular contractility, reducing scar volume and preventing progression to heart failure. We are developing two sustained release microsphere formulations of our API, recombinant non-glycosylated human FSTL1 - MyoBeads for delivery to acute MI patients via the infarct related artery at the time of percutaneous coronary revascularization, and Q-Beads, a subcutaneous microsphere formulation of FSTL1 for administration to patients with heart failure. Our core mission is to reduce morbidity and mortality from myocardial infarction, and to prevent the progression to heart failure following MI.

Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and reprogramming biology.

SalioGen is advancing a new category of genetic medicine we call Gene Coding, which works by adding a new genomic code to turn on, off or modify the functions of new or existing genes. We are advancing potentially curative therapies, with an initial focus on developing durable, safe and accessible genetic medicine to more patients with inherited disorders. At SalioGen, we are driven not only by our efforts to realize the immense potential of our science, but also by our dedication and commitment to developing medicines that can make a significant impact on patients’ lives. Our Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes we call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond. Looking ahead, SalioGen plans to explore Gene Coding’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing with the goal of helping an even broader population of patients in need.

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

Sangamo Therapeutics is a genomic medicine company conducting research & development across four distinct but complementary technology platforms – gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation. The optionality and diversity inherent to Sangamo’s technology platform enables us to design therapeutic approaches to resolve the underlying genetic causes of disease, using whichever technology is best suited to deliver that treatment. Because Sangamo’s technology platforms are related, we are applying learnings across studies to optimize each individual platform and uncover research and development paths forward. Sangamo is best known for developing our proprietary gene editing technology, zinc finger nucleases (ZFNs). Our technology team continues to optimize ZFNs for the three key dimensions of genome editing: precision, efficiency, and specificity. Ex vivo gene-edited cell therapy is the most straightforward application of ZFN technology. It builds on early experience with HIV clinical studies and is applied to hematological disorders and oncology. Our cell therapy portfolio also includes ex vivo engineered regulatory T-cells (CAR-Tregs) for application in autoimmunity and inflammation. The insights gained about molecular biology, cassette engineering, and delivery through in vivo application of ZFNs led to our gene therapy program using AAV, which is advancing in the clinic. Zinc finger protein engineering and AAV delivery are also foundational for our zinc finger protein-transcription factor (ZFP-TF) genome regulation technology, which we are applying in CNS diseases. With our robust history of genomic medicine firsts, unmatched technology platform, and growing manufacturing and clinical development capabilities, Sangamo believes we are the company to realize the vision of genomic medicine.

Sayenza Bio is a leading clinical stage biotechnology company committed to improving patient lives by harnessing the regenerative power of fat, the body’s largest source of stem cells, for limitless aesthetic and regenerative medicine applications. At Sayenza, our passionate, doctor-driven team unites cutting-edge scientific innovation with vast commercial expertise, propelling us towards transformative breakthroughs in healthcare. With a strong leadership team in place, extensive publications in leading journals, and top-tier KOLs signing up as early adopters, NESVF™ and Liquid Gold Graft™ are poised to become gold standards for stem cell and fat grafting applications and take a large chunk of the $6.25 billion aesthetics market.

A diagnosis of a serious illness can change life in an instant and finding treatment options is key. At Secura Bio®, we see things differently. We develop and commercialize innovative medicines and life changing products for the patients that need them most.

Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address. For more information, please visit the Senti Bio website at https://www.sentibio.com.

Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.

Simnova is a clinical stage biotech company focusing on the development of first/best-in-class cell therapy for cancer treatment.

Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.

Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

Styx, a pioneering biotech startup, is committed to transforming immunotherapy and cancer vaccine development by emphasizing enhanced immune memory for cancer treatment and prevention, particularly for challenging cancer types. The company's pipeline includes innovative CAR-T cell therapy product candidates targeting both solid and liquid tumors, as well as vaccine candidates addressing patient populations with high unmet medical need. With a mission to develop safer, more effective, and long-lasting immunotherapies and vaccines, Styx Biotechnologies is dedicated to improving global health outcomes and fostering a healthier future for all.

Sudhin Biopharma Co. is a biotechnology company developing efficient continuous biological manufacturing processes for therapeutic biologicals, sweet proteins, cell therapies and biological roducts.

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).

Theragent is a full-service cGMP Contract Development and Manufacturing Organization delivering innovative cell and gene therapy products to clients and patients around the world. Our expert staff and state of the art facility serves as a “one stop shopâ€? for all biopharma stakeholders seeking assistance in manufacturing and product development. Theragent’s cGMP facility features four manufacturing clean suites equipped with Digital DES technology, in house QC/QA, Microbiology, MSAT capabilities, and custom designed ERP system with paperless MBRs for real time reporting.

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Thunder Biotech, Inc. is an immune-oncology company developing patented MOTO-CAR™ technology - genetically engineered CAR macrophages - that help cancer patients' immune cells recognize and attack solid tumors. Traditional cancer treatments— like surgery, radiation, and chemotherapy—are often ineffective, invasive, and difficult to tolerate. Thunder Biotech is designing MOTO-CAR™s to be a more effective and humane therapy. Thunder Biotech's MOTO-CAR™s re-educate Tumor Associated Macrophages and restore their M1 ability to recognize and eliminate tumor cells. In addition, MOTO-CAR™s are armed with tumor specific receptors that directly adhere to the tumor cell surface allowing them to initiate tumor cell destruction and recruit the natural T cell response engaging them to eliminate the tumor. This T cell response will then provide the body with a memory response preventing tumor recurrence.

Tr1X Inc. (pr. "Trix")  is a biotechnology company dedicated to the development of novel cellular immunotherapies for patients with autoimmune and inflammatory diseases. The Company uses its proprietary platform for the generation of first-in-class cell therapy products aimed at rebalancing the immune system and restoring homeostasis, leading to long term tolerance. Tr1X is headquartered in La Jolla, CA.

We are driving CAR T therapy innovation to make it safer and more efficacious while improving accessibility and affordability. Our platforms are designed for rapid manufacturing and improved safety of autologous CAR T therapies, expanding access for patients with unmet medical needs. Stay tuned for groundbreaking advancements as we propel this therapy into uncharted territories.

We are a cancer therapeutics company with a mission to improve efficacy, reduce toxicity and increase treatment affordability of cancer drugs. We are an experienced team in cancer drug discovery and development. Team members have invented and developed drugs that are approved for cancer treatment. Our approach to eradicating cancer is distinct from the current standard of care. Current approaches involve single agent single action drugs that either inhibit cancer cell growth or inhibit immunosuppression, and hence, they are ineffective. These drugs are combined in a bid to improve efficacy. But combination leads to toxicity, poor efficacy, and high cost. We are developing single agent dual action treatments inhibiting both cancer growth and immunosuppression. We are not targeting the immune checkpoint axis. Our approach will be effective for cancer patients that failed immune checkpoint treatments due to resistance or low expression of PD1, PDL1, CTLA4 etc..

We are a biotechnology company focused on restoring cells’ youthful vigor to repair damage caused by the aging process. Using a proprietary ERA™ Platform, we develop mRNA medicines that are specially formulated to instruct specific cells in the body to fight disease or repair damaged tissue. We do this by reprogramming the epigenome to restore cell function that people often lose as they age. This approach can be used to revitalize different cells throughout the body – we are researching its applicability across multiple therapeutic areas, including dermatologic conditions, immunology, osteoarthritis and ophthalmology.

Umoja is developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.

U.S. Stem Cell, Inc. is a leader in regenerative medicine and is committed to providing autologous cell therapies for the treatment of degenerative conditions. The company specializes in the development of proprietary, physician-based stem cell therapies; novel regenerative solutions, including its lead product AdipoCell™; physician training and certification; veterinary applications; stem cell banking; as well as creating and managing new stem cell clinics. In the past 20 years, to the company’s knowledge, U.S. Stem Cell, Inc. has completed more clinical treatments than any other regenerative care provider in the world. With more than 700 physicians trained and certified with the company, U.S. Stem Cell, Inc. boasts the largest network of physicians working together to continue its mission of harnessing the body’s own ability to heal from within to treat a wide variety of conditions and to improve quality of life.

U.S. Stem Cell, Inc. is a leader in regenerative medicine and is committed to providing autologous cell therapies for the treatment of degenerative conditions. The company specializes in the development of proprietary, physician-based stem cell therapies; novel regenerative solutions, including its lead product AdipoCell™; physician training and certification; veterinary applications; stem cell banking; as well as creating and managing new stem cell clinics. In the past 20 years, to the company’s knowledge, U.S. Stem Cell, Inc. has completed more clinical treatments than any other regenerative care provider in the world. With more than 700 physicians trained and certified with the company, U.S. Stem Cell, Inc. boasts the largest network of physicians working together to continue its mission of harnessing the body’s own ability to heal from within to treat a wide variety of conditions and to improve quality of life.

Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.

Vironexis is focused on transforming the future of cancer treatment by pioneering AAV-delivered T-cell immunotherapy. Our TransJoin™ AAV Gene Therapy Platform enables the creation of off-the-shelf, single-dose gene therapies designed to overcome the key challenges and shortcomings of current immunotherapies, including CAR-T and bispecific antibodies. Our current pipeline includes more than ten product candidates for blood-based cancers, solid tumor metastasis prevention, and a cancer vaccine. Our lead program, VNX-101, for the treatment of CD19+ acute lymphoblastic leukemia, is anticipated to begin clinical trials in the fourth quarter of 2024.

Visicell Medical Inc. was founded by a team of passionate scientist, engineer, and radiologist with a singular goal: to help accelerate stem cell-based therapy to the market for patients who are afflicted with devastating and currently incurable diseases. Our technology platform will transform how biopharmaceutical products are developed and taken to market by offering customers clinically applicable imaging tools that can provide real-time insights for their unique individual research needs.

Vittoria Biotherapeutics is committed to unlocking the promise of cell therapies while addressing their inherent challenges by strengthening efficacy, improving safety, and broadening therapeutic applicability for patients with difficult-to-treat diseases. An Important Note About Privacy: Vittoria Biotherapeutics is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth, or bank account details via email, job recruiting, or social media platforms. We do not hire virtually or solicit/interview candidates on Indeed, Telegram, Wire, Google Hangouts or similar public platforms. Any questions about career opportunities can be directed to info@vittoriabio.com.

We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.

Wugen is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. Wugen is based out of St. Louis, Missouri and San Diego, California.

WuXi Advanced Therapies - Accelerating Progress and Time to Market WuXi Advanced Therapies is a cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) that is reducing the complexities of manufacturing by providing integrated platforms that enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability. Our Story By leveraging platforms and integrated testing our team provides expedited development and commercialization of cell, gene, protein and viral-based therapies. This approach enables new biopharmaceuticals to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities of high-touch, multi-vendor production models. Our solutions help clients overcome challenges to commercialization, including process development, manufacturing capacity, analytical development, and raw materials management. Multiple, scale-able, enabling platforms integrate manufacturing, process development and testing capabilities to provide greater predictability and speed to clinic. We support advanced therapy programs with extensive infrastructure and 400,000+ square feet of state-of-the-art, GMP-compliant facilities on our modern campus located at the Navy Yard in Philadelphia, Pennsylvania.

At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.

Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

We partner with companies to create innovative solutions, driving the advancement of revolutionary medicine. Our primary goal is for patients to receive therapies more efficiently, while keeping safety and quality at the absolute forefront. We specialize in producing cutting-edge equipment for downstream processing, particularly in the critical stages of fill and finish. Additionally, we have expertise in designing tailor-made equipment for cell and gene therapy.

Xpan is Developing the Next Generation of Minimally Invasive Surgical Access Ports

At Xyphos, we’re working to deliver flexible and adaptable cancer therapies with the potential to revolutionize cancer care.